Cargando…
Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
BACKGROUND: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. OBJECTIVES: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in patients with chronic plaque psoriasis treated with...
Autores principales: | Rungapiromnan, W., Mason, K.J., Lunt, M., McElhone, K., Burden, A.D., Rutter, M.K., Warren, R.B., Griffiths, C.E.M., Ashcroft, D.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155017/ https://www.ncbi.nlm.nih.gov/pubmed/31633837 http://dx.doi.org/10.1111/jdv.16018 |
Ejemplares similares
-
Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
por: Mrowietz, U., et al.
Publicado: (2021) -
Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis
por: Gooderham, M., et al.
Publicado: (2022) -
Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
por: Papp, K.A., et al.
Publicado: (2018) -
Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis
por: Iskandar, I.Y.K., et al.
Publicado: (2017) -
Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom
por: Warren, R.B., et al.
Publicado: (2018)